Skip to main content
OpenTrials
Completed

NCT Number: NCT02834130

Input of a Multidisciplinary Device to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families

Severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. In last decades, news therapies have dramatically increased life expectancy and joint's protection.

The investigators propose to set up a single-centre, descriptive, transversal pilot study, designed for the inclusion of around thirty children from 2 to 10 years, with haemophilia or allied hereditary bleeding disorders (HBD), who were referred to the Hemophilia Treatment Center (HTC) of Marseille at diagnosis. For those children who were able to benefit from the totality or part of the device accompanying the diagnostic announcement in the past 10 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Enfants de la Timone Assistance Publique Hôpitaux de Marseille

Marseille, 13354, France

About this study

Severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. In last decades, news therapies have dramatically increased life expectancy and joint's protection. The recurrence of joint bleedings is responsive of multifocal arthropathy in the natural history, but nowadays, the orthopedic outcome is good thanks to prophylactic treatments.

However, the announcement of the diagnosis of such hereditary bleeding disorders at a very young age represents a real psychological trauma for parents. Such an announcement may induce some psycho-developmental impairment.

An innovative support has been implemented at the Hemophilia Treatment Center in Marseille, in conjunction with the French Hemophilia Society. This program is based on a multidisciplinary partnership that favors the psychological support and the reinsurance of the parents.

With Rare Diseases Foundation support, the investigators have initiated this pilot study that will include more than 20 patients with severe hemophilia or constitutional bleeding disorder, who benefit from the device. This descriptive, monocentric, interventional study will permit to describe the psychological status, the quality of life of patients and their parents, but also to evaluate the impact of the device on initiation and observance of treatments like Long Term Prophylaxis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged between 3 and 12 years
  • Patients diagnosed and treated at the Center until inclusion
  • Patients with FVIII :C < 2% or with FIX :C <2% or with FVII:C <2% or with FXIII:C <2% or fibrinogen <0,2 g/l, or with type 3 von Willebrand diseases or Thrombasthenia of Glanzmann diseases.
  • Patient who participate to multidisciplinary support and announcement of diagnosis device
  • Voluntarily given fully informed written and signed consents obtained before any study-related procedures are conducted

Exclusion criteria

  • Patient with other clotting disorder or disease.
  • Patient diagnosed or treated in other centre
  • Patient with psychiatric disorder or disease
  • Patient with other severe chronic disease

Treatment and study plan

Evaluation of psychological and psychopathological

Behavioral

Other names: Evaluation of quality of life

Primary outcomes

  1. Number of Treatment Exposure Days compared to the Number of Treatment Exposure days prescribed

    Time frame: 2 years

    Treatment Observance

Secondary outcomes

  1. Assessment of patient's behavioral condition using the Child Behavior Check-list (CBCL) 1,5-5

    Time frame: 2 Years

  2. Assessment of the patient's body consciousness through the "CORP-R" test (french test of body mapping)

    Time frame: 2 years

  3. Assessment of patient's quality of life using the "Kidscreen" questionnaire for children

    Time frame: 2 years

  4. Assessment of the patient's parents' Qaulity of life through the Short Form Health Survey (SF-36)

    Time frame: 2 Years

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Official study title

Input of a Multidisciplinary Device Including a Psychological Approach, to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families

Acronym: ACADHEM

Important dates

Study start
2014
Primary completion
2016
First posted
Jul 15, 2016
Registry last updated
Jul 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.